JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (3): 24-29.doi: 10.6040/j.issn.1671-7554.0.2015.359

Previous Articles     Next Articles

CXXC4 promotes sensitivity to chemotherapy drugs in epithelial ovarian cancer cells

ZHAO Yunxia, SONG Jing, ZHANG Cancan, LIN Xueyan, WEI Wei, TIAN Yongjie   

  1. Department of Obstetrics and Gynecology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China
  • Received:2015-04-08 Online:2016-03-10 Published:2016-03-10

PDF (PC)

266

Abstract: Objective To explore the effect of CXXC4 on the proliferation and sensitivity to chemotherapy drugs in ovarian carcinoma cells. Methods Protein and mRNA levels of CXXC4 were detected in nomal ovarian epithelial cells and ovarian carcinoma cells by Western blotting and Real-time PCR, respectively. The recombinant plasmid pcDNA3-CXXC4 and siRNA-CXXC4 were transfected into SKOV3, Caov3 cells and IOSE80 cells via Lipo2000. CCK8 assay was used to evaluate the effect of CXXC4 on the proliferation and sensitivity to chemotherapy drugs. Results Compared with the normal ovarian epithelial cells, CXXC4 expression was lower in ovarian carcinoma cells. Overexpression of CXXC4 inhibited the proliferation capacity and increased the sensitivity to chemotherapy drugs in SKOV3 and Caov3 cells. Decreased CXXC4 expression could promote the proliferation capacity and the chemo-resistance to chemotherapy drugs of normal ovarian epithelial cells. Conclusion Overexpression of CXXC4 could inhibit the proliferation capacity and increase the sensitivity to chemotherapy drugs in ovarian carcinoma cells, suggesting it would be a potential biomarker to predict the efficacy or a molecular target to enhance the efficacy to chemotherapy in ovarian carcinoma cells.

Key words: Ovarian cancer, Chemo-resistance, CXXC4, Proliferation

CLC Number: 

  • R737.31
[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2):69-90.
[2] 陈万青,张思维,曾红梅,等.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤, 2014, 23(1):1-10. CHEN Wanqing, ZHANG Siwei, ZENG Hongmei, et al. Report of cancer incidence and mortality in China, 2010[J]. China Cancer, 2014, 23(1):1-10.
[3] Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer[J]. CA Cancer J Clin, 2011, 61(3):183-203.
[4] Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer[J]. N Engl J Med, 2010, 363(10):943-953.
[5] Cannistra SA. Cancer of the ovary[J]. N Engl J Med, 2004, 351(24):2519-2529.
[6] Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24(Suppl 6):vi24-vi32.
[7] Jemal A, Siegel R, Xu J, et al. Cancer statistics[J]. CA Cancer J Clin, 2010, 60(5):277-300.
[8] Hino S, Kishida S, Michiue T, et al. Inhibition of the Wnt signaling pathway by Idax, a novel Dvl-binding protein[J]. Mol Cell Biol, 2001, 21(1):330-342.
[9] Michiue T, Fukui A, Yukita A, et al. XIdax, an inhibitor of the canonical Wnt pathway, is required for anterior neural structure formation in Xenopus [J]. Dev Dyn, 2004, 230(1):79-90.
[10] Kojima T, Shimazui T, Hinotsu S, et al. Decreased expression of CXXC4 promotes a malignant phenotype in renal cell carcinoma by activating Wnt signaling [J]. Oncogene, 2009, 28(2):297-305.
[11] Colombo PE, Fabbro M, Theillet C, et al. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer [J]. Crit Rev Oncol/Hematol, 2014, 89(2):207-216.
[12] Thigpen T. A rational approach to the management of recurrent or persistent ovarian carcinoma [J]. Clin Obstet Gynecol, 2012, 55(1):114-130.
[13] Abada P, Howell SB. Regulation of Cisplatin cytotoxicity by cu influx transporters [J]. Metal Based Drugs, 2010:317581. doi:10.1155/2010/317581.
[14] Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer [J]. BMC Cancer, 2006, 6:201.
[15] Surowiak P, Materna V, Kaplenko I, et al. Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients[J]. Virchows Arch, 2005, 447(3):626-633.
[16] Kobayashi Y, Seino K, Hosonuma S, et al. Side population is increased in paclitaxel-resistant ovarian cancer cell lines regardless of resistance to cisplatin[J]. Gynecol Oncol, 2011, 121(2):390-394.
[17] Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant[J]. Br J Cancer, 2010, 102(8):1276-1283.
[18] Wang QE, Han C, Milum K, et al. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment[J]. Mutat Res, 2011, 708(1-2):59-68.
[19] Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance[J]. Cell Cycle, 2009, 8(1):158-166.
[20] Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells[J]. Stem Cells, 2009, 27(9):2059-2068.
[21] Lu H, Sun J, Wang F, et al. Enhancer of zeste homolog 2 activates wnt signaling through downregulating CXXC finger protein 4[J]. Cell Death Dis, 2013, 4:e776. doi:10.1038/cddis.2013.293.
[22] Lu H, Jin W, Sun J, et al. New tumor suppressor CXXC finger protein 4 inactivates mitogen activated protein kinase signaling[J]. FEBS Lett, 2014, 588(18):3322-3326.
[23] Arend RC, Londono-Joshi AI, Straughn JM, et al. The Wnt/beta-catenin pathway in ovarian cancer:a review [J]. Gynecol Oncol, 2013, 131(3):772-779.
[24] Fan HY, Liu Z, Mullany LK, et al. Consequences of RAS and MAPK activation in the ovary:the good, the bad and the ugly [J]. Mol Cell Endocrinol, 2012, 356(1-2):74-79.
[25] Grendys EC, Wang D, Tian C, et al. Overview of a chemoresponse assay in ovarian cancer [J]. Clin Transl Oncol, 2014, 16(9):761-769.
[26] Han Y, Huang H, Xiao Z, et al. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer [J]. PloS One, 2012, 7(12):e52745. doi:10.1371/journal.pone.0052745.
[1] WANG Xiao-Lei, ZHANG Hai-Thao, ZHANG Hui, GUO Cheng-Hao. Protective effects of shuxuening injecta on vascular  endothelial  cell injury in vitro due to iodine excesses [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2209, 47(6): 38-.
[2] SUN Yifeng, GAO Yu, LIANG Yongyuan, GAO Yang. Expression of CPLX2 and its in vitro effects on the proliferation migration and invasion of hepatocellular carcinoma cells [J]. Journal of Shandong University (Health Sciences), 2020, 1(9): 34-39.
[3] ZHANG Baowen, LEI Xiangli, LI Jinna, LUO Xiangjun, ZOU Rong. miR-21-5p targeted TIMP3 to inhibit proliferation and extracellular matrix accumulation of mesangial cells in Type II diabetic nephropathy mice [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 7-14.
[4] MA Qingyuan, PU Peidong, HAN Fei, WANG Chao, ZHU Zhoujun, WANG Weishan, SHI Chenhui. Effect of miR-27b-3p regulating SMAD1 on osteosarcoma cell proliferation, migration and invasion [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 32-37.
[5] LI Ning, LI Juan, XIE Yan, LI Peilong, WANG Yunshan, DU Lutao, WANG Chuanxin. Expression of LncRNA AL109955.1 in 80 cases of colorectal cancer and its effect on cell proliferation, migration and invasion [J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 38-46.
[6] WANG Kaimin, TAN Juanjuan, YAN Zhiqiang, LI Zhiqiang. Effects of Sirtuin on hypoxia-induced proliferation of human umbilical cord-derived mesenchymal stem cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(7): 23-30.
[7] SHI Peikun, ZENG Beini, WU Weifang, HU Xiaoyan, MA Tianjia, ZHOU Yabin. Expression and role of Keap1 in renal cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(3): 94-99.
[8] SUN Zeyu, CHEN Ying, LIN Jiaxiang, LIU Juan, ZHAO Weiming. Influence of inositol polyphosphate-4-phosphatase type II on the proliferation and apoptosis of cervical cancer cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 1-6.
[9] WANG Tiantian, CHEN Jie. Expression and clinical significance of EFEMP2 in endometrial cancer tissues and cell [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(10): 52-58.
[10] LU Heng, LIU Yanguo, LI Shuguang, CHEN Xiaokang, TIAN Qi, YI Cuihua, WANG Xiuwen. Regulation of epithelial ovarian carcinoma SKOV-3 cell migration by YKL-40 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 33-38.
[11] ZHAO Lu, JIAO Jun, ZHANG Teng, JIAO Xinlin, CUI Baoxia. Expression of LXRα in ovarian carcinoma and effects of T0901317 on SKOV3 cell line [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(1): 49-53.
[12] TIAN Siqi, LIU Riqiang, YANG Ning, WEI Wei, YANG Huawei. Effect of expression of ribosomal protein S6 Kinase 4 variants on the proliferation of breast cancer cell MDA-MB-231 [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 32-36.
[13] WEI Xiujuan, WU Xiuyin, TONG Dongdong, LI Jing, YANG Xiaolu, ZHANG Fenghe. Expression of BDNF/TrkB and effect of BDNF on the proliferation ability of tongue squamous cell carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(6): 50-54.
[14] XIAO Junchao, JIANG Wen, NAN Hui, WANG Peirong. A recombinant adenovirus fiber knob protein sensitizes ovarian cancer cells to cetuximab therapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 1-5.
[15] XU Zhihong, WU Xiaohua, YAO Tiezhu, WANG Xiaoxiang, DUAN Xiaoyang, SHI Jian. Relationship between mir-99a expression and prognosis of epithelial ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(3): 77-80.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd